
Acquisition - November 1, 2021
AstraZeneca to transfer global rights for Eklira and Duaklir
AstraZeneca has agreed to transfer its global rights to Eklira (aclidinium bromide), known as Tudorzain the US, and Duaklir (aclidinium bromide/formoterol) to Covis Pharma. Both medicines are delivered via the Genuair device and used for the treatment of patients with chronic obstructive pulmonary disease (COPD). The agreement will ensure continued patient access to these established […]